The impact of PC exposure on the incidence of TEAMV-PD was determined by a Bayesian regression model to compare treatment groups. The model adjusted for baseline covariates using a normal distribution with large variance as a noninformative prior on the regression coefficients. Results were adjusted by baseline primary disease therapy strata, cardiac disease history, pulmonary disease history and transfusion reaction history. Treatment group as well as any additional covariates were included as fixed-level effects. Risk ratios and their associated credible intervals, along with the posterior probability of superiority for the treatment group, are shown. The probability that PRPC were superior to CPC for lower incidence of TEAMV-PD is >90% for patients exposed from 5 to 10 and ≥10 PCs. For all patients, the probability of PRPC superiority is 99.2% in this model. For patients with limited exposures (1 PC and 2-4 PCs), PRPC is superior but with lower probability (66.3% and 73.3%, respectively).